Hosted on MSN3mon
Revolutionary obesity and diabetes treatment burns energy and reduces appetite without side effects
Recent advances in glucagon receptor (GCGR) agonists show promise for enhancing catabolic metabolism, but concerns persist. Potential side effects include increased heart rates, hepatic glucose ...
Yahoo Finance24d
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon receptor (GCGR), Glucagon-like peptide-1 receptor (GLP-1R) has completed the ...
American Association of Individual Investors3d
Why Structure Therapeutics Inc.’s (GPCR) Stock Is Down 12.27%
Structure Therapeutics Inc.’s GPCR share price has dipped by 12.27%, which has investors questioning if this is right time to buy.
EurekAlert!6mon
Potential candidates for MASLD and their mechanisms of action (IMAGE)
ACC, Acetyl-CoA Carboxylase; PPAR, peroxisome proliferator–activated receptor; MPC, mitochondrial pyruvate carrier; THR, thyroid hormone receptor; ASK-1, apoptosis signaling kinase-1; GLP-1R ...
Yahoo Finance24d
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon receptor (GCGR), Glucagon-like peptide-1 receptor (GLP-1R) has completed the enrollment ...